Compare Marathon Petroleum Corp (MPC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Tango Therapeutics Inc. — how do they compare? Marathon Petroleum Corp trades at $484.5 (market cap $136.18B), while Tango Therapeutics Inc. trades at $22.1 (market cap $3.74B). The key difference: Marathon Petroleum Corp is far larger — about 36.4× Tango Therapeutics Inc.'s market cap, and Marathon Petroleum Corp pays a 0.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| MPC | TNGX | |
|---|---|---|
Market Cap | $136.18B | $3.74B |
Volume | 1,631,475 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $484.92 | $32.90 |
52-Week Low | $162.63 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $162.70B | $2.76B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $476.98, up 3.96% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.81, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export policies and volatile energy markets.
MPC presents a compelling investment case with solid fundamentals, earnings momentum, and a unanimous buy rating from analysts. However, investors face risks from regulatory uncertainty and cyclical energy demand. The stock's current price near resistance at $479 requires monitoring for breakout or pullback opportunities.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
